Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2007

Open Access 01-12-2007 | Hypothesis

The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes

Authors: Raffaele Marfella, Michele D' Amico, Clara Di Filippo, Mario Siniscalchi, Ferdinando Carlo sasso, Franca Ferraraccio, Francesco Rossi, Giuseppe Paolisso

Published in: Cardiovascular Diabetology | Issue 1/2007

Login to get access

Abstract

We have reviewed the impact of the ubiquitin proteasome system (UPS) on atherosclerosis progression of diabetic patients. A puzzle of many pieces of evidence suggests that UPS, in addition to its role in the removal of damaged proteins, is involved in a number of biological processes including inflammation, proliferation and apoptosis, all of which constitute important characteristics of atherosclerosis. From what can be gathered from the very few studies on the UPS in diabetic cardiovascular diseases published so far, the system seems to be functionally active to a different extent in the initiation, progression, and complication stage of atherosclerosis in the diabetic people. Further evidence for this theory, however, has to be given, for instance by specifically targeted antagonism of the UPS. Nonetheless, this hypothesis may help us understand why diverse therapeutic interventions, which have in common the ability to reduce ubiquitin-proteasome activity, can impede or delay the onset of diabetes and cardiovascular diseases (CVD).
People with type 2 diabetes are disproportionately affected by CVD, compared with those without diabetes [1]. The prevalence, incidence, and mortality from all forms of CVD (myocardial infarction, cerebro-vascular disease and congestive heart failure) are strikingly increased in persons with diabetes compared with those withoutdiabetes [2]. Furthermore, diabetic patients have not benefited by the advances in the management of obesity, dyslipidemia, and hypertension that have resulted in a decrease in mortality for coronary heart disease (CHD) patients without diabetes [3]. Nevertheless, these risk factors do not fully explain the excess risk for CHD associated with diabetes [4, 5]. Thus, the determinants of progression of atherosclerosis in persons with diabetes must be elucidated. Beyond the major risk factors, several studies have demonstrated that such factors, strictly related to diabetes, as insulin-resistance, post-prandial hyperglycemia and chronic hyperglycemia play a role in the atherosclerotic process and may require intervention [6, 7]. Moreover, it is important to recognize that these risk factors frequently "cluster" inindividual patients and possibly interact with each other, favouring the atherosclerosis progression toward plaque instability. Thus, a fundamental question is, "which is the common soil hypothesis that may unifying the burden of all these factors on atherosclerosis of diabetic patients? Because evidences suggest that insulin-resistance, diabetes and CHD share in common a deregulation of ubiquitin-proteasome system (UPS), the major pathway for nonlysosomal intracellular protein degradation in eucaryotic cells [8, 9], in this review ubiquitin-proteasome deregulation is proposed as the common persistent pathogenic factor mediating the initial stage of the atherosclerosis as well as the progression to complicated plaque in diabetic patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kannel WB, McGee DL: Diabetes and cardiovascular diseases. The Framingham Study. JAMA. 1979, 241: 2035-2038. 10.1001/jama.241.19.2035.CrossRefPubMed Kannel WB, McGee DL: Diabetes and cardiovascular diseases. The Framingham Study. JAMA. 1979, 241: 2035-2038. 10.1001/jama.241.19.2035.CrossRefPubMed
2.
go back to reference Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO: Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2002, 105: 2231-2239. 10.1161/01.CIR.0000013952.86046.DD.CrossRefPubMed Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO: Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2002, 105: 2231-2239. 10.1161/01.CIR.0000013952.86046.DD.CrossRefPubMed
3.
go back to reference Kempler P: Learning from large cardiovascular clinical trials: classical cardiovascular risk factors. Diabetes Res Clin Pract. 2005, 68: S43-S47. 10.1016/j.diabres.2005.03.005.CrossRefPubMed Kempler P: Learning from large cardiovascular clinical trials: classical cardiovascular risk factors. Diabetes Res Clin Pract. 2005, 68: S43-S47. 10.1016/j.diabres.2005.03.005.CrossRefPubMed
4.
go back to reference Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes. other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993, 16: 434-44. 10.2337/diacare.16.2.434.CrossRefPubMed Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes. other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993, 16: 434-44. 10.2337/diacare.16.2.434.CrossRefPubMed
5.
go back to reference Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J: Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry study. Diabetes Care. 1997, 20: 163-169. 10.2337/diacare.20.2.163.CrossRefPubMed Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J: Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry study. Diabetes Care. 1997, 20: 163-169. 10.2337/diacare.20.2.163.CrossRefPubMed
6.
go back to reference Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002, 25: 1129-1134. 10.2337/diacare.25.7.1129.CrossRefPubMed Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002, 25: 1129-1134. 10.2337/diacare.25.7.1129.CrossRefPubMed
7.
go back to reference Fonseca V, Desouza C, Asnani S, Jialal I: Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev. 2004, 25: 153-175. 10.1210/er.2002-0034.CrossRefPubMed Fonseca V, Desouza C, Asnani S, Jialal I: Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev. 2004, 25: 153-175. 10.1210/er.2002-0034.CrossRefPubMed
8.
go back to reference Hershko A, Ciechanover A, Varshavsky A: Basic medical research award. The ubiquitin system. Nat Med. 2002, 6: 1073-1081. 10.1038/80384.CrossRef Hershko A, Ciechanover A, Varshavsky A: Basic medical research award. The ubiquitin system. Nat Med. 2002, 6: 1073-1081. 10.1038/80384.CrossRef
9.
go back to reference Herrmann J, Ciechanover A, Lerman LO, Lerman A: The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc Res. 2004, 61: 11-21. 10.1016/j.cardiores.2003.09.033.CrossRefPubMed Herrmann J, Ciechanover A, Lerman LO, Lerman A: The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc Res. 2004, 61: 11-21. 10.1016/j.cardiores.2003.09.033.CrossRefPubMed
10.
go back to reference Ciechanover A, Hod Y, Hershko A: A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun. 1978, 81: 1100-1105. 10.1016/0006-291X(78)91249-4.CrossRef Ciechanover A, Hod Y, Hershko A: A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun. 1978, 81: 1100-1105. 10.1016/0006-291X(78)91249-4.CrossRef
11.
go back to reference Mitch WE, Goldberg AL: Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996, 335: 1897-1905. 10.1056/NEJM199612193352507.CrossRefPubMed Mitch WE, Goldberg AL: Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996, 335: 1897-1905. 10.1056/NEJM199612193352507.CrossRefPubMed
12.
go back to reference Arrigo AP, Tanaka K, Goldberg AL, Welch WJ: Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells the proteasome. Nature. 1998, 331: 192-194. 10.1038/331192a0.CrossRef Arrigo AP, Tanaka K, Goldberg AL, Welch WJ: Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells the proteasome. Nature. 1998, 331: 192-194. 10.1038/331192a0.CrossRef
13.
go back to reference Hicke L, Schubert HL, Hill CP: Ubiquitin-binding domains. Nat Rev Mol Cell Biol. 2005, 6: 610-621. 10.1038/nrm1701.CrossRefPubMed Hicke L, Schubert HL, Hill CP: Ubiquitin-binding domains. Nat Rev Mol Cell Biol. 2005, 6: 610-621. 10.1038/nrm1701.CrossRefPubMed
14.
go back to reference Goldberg AL: Protein degradation and protection against misfolded or damaged proteins. Nature. 2003, 426: 895-899. 10.1038/nature02263.CrossRefPubMed Goldberg AL: Protein degradation and protection against misfolded or damaged proteins. Nature. 2003, 426: 895-899. 10.1038/nature02263.CrossRefPubMed
15.
go back to reference Palombella VJ, Rando J, Goldberg A, Maniatis T: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994, 78: 773-785. 10.1016/S0092-8674(94)90482-0.CrossRefPubMed Palombella VJ, Rando J, Goldberg A, Maniatis T: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994, 78: 773-785. 10.1016/S0092-8674(94)90482-0.CrossRefPubMed
16.
go back to reference Wilson SH, Caplice NM, Simari RD, Holmes DR, Carlson PJ, Lerman A: Activated nuclear factor-kappaB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis. 2000, 148: 23-30. 10.1016/S0021-9150(99)00211-7.CrossRefPubMed Wilson SH, Caplice NM, Simari RD, Holmes DR, Carlson PJ, Lerman A: Activated nuclear factor-kappaB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis. 2000, 148: 23-30. 10.1016/S0021-9150(99)00211-7.CrossRefPubMed
18.
go back to reference Ishii T, Itoh K, Sato H, Bannai S: Oxidative stress-inducible proteins in macrophages. Free Radic Res. 1999, 31: 351-355. 10.1080/10715769900300921.CrossRefPubMed Ishii T, Itoh K, Sato H, Bannai S: Oxidative stress-inducible proteins in macrophages. Free Radic Res. 1999, 31: 351-355. 10.1080/10715769900300921.CrossRefPubMed
19.
go back to reference Kikuchi J, Furukawa Y, Kubo N: Induction of ubiquitin-conjugating enzyme by aggregated low density lipoprotein in human macrophages and its implications for atherosclerosis. Arterioscler Thromb Vasc Biol. 2000, 20: 128-134.CrossRefPubMed Kikuchi J, Furukawa Y, Kubo N: Induction of ubiquitin-conjugating enzyme by aggregated low density lipoprotein in human macrophages and its implications for atherosclerosis. Arterioscler Thromb Vasc Biol. 2000, 20: 128-134.CrossRefPubMed
20.
go back to reference Versari D, Herrmann J, Gössl M, Mannheim D, Sattler K, Meyer FB, Lerman LO, Lerman A: Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2006, 26: 2132-2139. 10.1161/01.ATV.0000232501.08576.73.CrossRefPubMed Versari D, Herrmann J, Gössl M, Mannheim D, Sattler K, Meyer FB, Lerman LO, Lerman A: Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2006, 26: 2132-2139. 10.1161/01.ATV.0000232501.08576.73.CrossRefPubMed
21.
go back to reference Marfella R, D'Amico M, Di Filippo C, Baldi A, Siniscalchi M, Sasso FC, Portoghese M, Carbonara O, Crescenzi B, Sangiuolo P, Nicoletti GF, Rossiello R, Cacciapuoti F, Verza M, Coppola L, Rossi F, Paolisso G: Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol. 2006, 47: 2444-2455. 10.1016/j.jacc.2006.01.073.CrossRefPubMed Marfella R, D'Amico M, Di Filippo C, Baldi A, Siniscalchi M, Sasso FC, Portoghese M, Carbonara O, Crescenzi B, Sangiuolo P, Nicoletti GF, Rossiello R, Cacciapuoti F, Verza M, Coppola L, Rossi F, Paolisso G: Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol. 2006, 47: 2444-2455. 10.1016/j.jacc.2006.01.073.CrossRefPubMed
22.
go back to reference Siebenlist U, Franzoso G, Brown K: Structure. regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994, 10: 405-455. 10.1146/annurev.cb.10.110194.002201.CrossRefPubMed Siebenlist U, Franzoso G, Brown K: Structure. regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994, 10: 405-455. 10.1146/annurev.cb.10.110194.002201.CrossRefPubMed
23.
go back to reference Herrmann J, Gulati R, Napoli C, Woodrum JE, Lerman LO, Rodriguez-Porcel M: Oxidative stress-related increase in ubiquitination in early coronary atherosclerosis. FASEB J. 2003, 17: 1730-1732. Herrmann J, Gulati R, Napoli C, Woodrum JE, Lerman LO, Rodriguez-Porcel M: Oxidative stress-related increase in ubiquitination in early coronary atherosclerosis. FASEB J. 2003, 17: 1730-1732.
24.
go back to reference Nigro J, Osman N, Dart AM, Little PJ: Insulin Resistance and Atherosclerosis. Endocrine Reviews. 2006, 27: 242-259. 10.1210/er.2005-0007.CrossRefPubMed Nigro J, Osman N, Dart AM, Little PJ: Insulin Resistance and Atherosclerosis. Endocrine Reviews. 2006, 27: 242-259. 10.1210/er.2005-0007.CrossRefPubMed
25.
go back to reference Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ: Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000, 101: 1539-1545.CrossRefPubMed Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ: Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000, 101: 1539-1545.CrossRefPubMed
26.
go back to reference Komalavilas P, Shah PK, Jo H, Lincoln TM: Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem. 1999, 274: 34301-3439. 10.1074/jbc.274.48.34301.CrossRefPubMed Komalavilas P, Shah PK, Jo H, Lincoln TM: Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem. 1999, 274: 34301-3439. 10.1074/jbc.274.48.34301.CrossRefPubMed
27.
go back to reference Wang X, Hu Z, Hu J, Du J, Mitch WE: Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signalling. Endocrinology. 2006, 147: 4160-4168. 10.1210/en.2006-0251.CrossRefPubMed Wang X, Hu Z, Hu J, Du J, Mitch WE: Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signalling. Endocrinology. 2006, 147: 4160-4168. 10.1210/en.2006-0251.CrossRefPubMed
28.
go back to reference Balasubramanyam M, Sampathkumar R, Mohan V: Is insulin signaling molecules misguided in diabetes for ubiquitin-proteasome mediated degradation?. Mol Cell Biochem. 2005, 275: 117-1125. 10.1007/s11010-005-1083-y.CrossRefPubMed Balasubramanyam M, Sampathkumar R, Mohan V: Is insulin signaling molecules misguided in diabetes for ubiquitin-proteasome mediated degradation?. Mol Cell Biochem. 2005, 275: 117-1125. 10.1007/s11010-005-1083-y.CrossRefPubMed
29.
go back to reference Pallares-Trujillo J, Carbo N, Lopez-Soriano FJ, Argiles JM: Does the mechanism responsible for TNF-mediated insulin resistance involve the proteasome?. Med Hypotheses. 2000, 54: 565-569. 10.1054/mehy.1999.0895.CrossRefPubMed Pallares-Trujillo J, Carbo N, Lopez-Soriano FJ, Argiles JM: Does the mechanism responsible for TNF-mediated insulin resistance involve the proteasome?. Med Hypotheses. 2000, 54: 565-569. 10.1054/mehy.1999.0895.CrossRefPubMed
30.
go back to reference Medina EA, Afsari RR, Ravid T, Castillo SS, Erickson KL, Goldkorn T: Tumor necrosis factor-{alpha} decreases Akt protein levels in 3T3-L1 adipocytes via the caspase-dependent ubiquitination of Akt. Endocrinology. 2006, 146: 2726-2735. 10.1210/en.2004-1074.CrossRef Medina EA, Afsari RR, Ravid T, Castillo SS, Erickson KL, Goldkorn T: Tumor necrosis factor-{alpha} decreases Akt protein levels in 3T3-L1 adipocytes via the caspase-dependent ubiquitination of Akt. Endocrinology. 2006, 146: 2726-2735. 10.1210/en.2004-1074.CrossRef
31.
go back to reference Fujita T, Doihara H, Washio K, Kawasaki K, Takabatake D, Takahashi H, Tsukuda K, Ogasawara Y, Shimizu N: Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs. 2006, 17: 455-462. 10.1097/01.cad.0000198910.90819.06.CrossRefPubMed Fujita T, Doihara H, Washio K, Kawasaki K, Takabatake D, Takahashi H, Tsukuda K, Ogasawara Y, Shimizu N: Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs. 2006, 17: 455-462. 10.1097/01.cad.0000198910.90819.06.CrossRefPubMed
32.
go back to reference Del Prato S: Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia. 2003, 46: M2-M8.PubMed Del Prato S: Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia. 2003, 46: M2-M8.PubMed
33.
go back to reference Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.CrossRefPubMed Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.CrossRefPubMed
34.
35.
go back to reference Ceriello A: Postprandial hyperglycemia and diabetes complications is it time to treat?. Diabetes. 2005, 54: 1-7. 10.2337/diabetes.54.1.1.CrossRefPubMed Ceriello A: Postprandial hyperglycemia and diabetes complications is it time to treat?. Diabetes. 2005, 54: 1-7. 10.2337/diabetes.54.1.1.CrossRefPubMed
36.
go back to reference Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F: Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation. 1997, 95: 1783-1790.CrossRefPubMed Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F: Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation. 1997, 95: 1783-1790.CrossRefPubMed
37.
go back to reference Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2000, 414: 813-820. 10.1038/414813a.CrossRef Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2000, 414: 813-820. 10.1038/414813a.CrossRef
38.
go back to reference Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T: Upregulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett. 2005, 360: 291-293. 10.1016/0014-5793(95)00124-R.CrossRef Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T: Upregulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett. 2005, 360: 291-293. 10.1016/0014-5793(95)00124-R.CrossRef
39.
go back to reference Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 2005, 271: C1424-C1437. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 2005, 271: C1424-C1437.
40.
go back to reference Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D: Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest. 2001, 108: 635-636. 10.1172/JCI0113727A.PubMedCentralCrossRefPubMed Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D: Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest. 2001, 108: 635-636. 10.1172/JCI0113727A.PubMedCentralCrossRefPubMed
41.
go back to reference Ceriello A, Quagliaro L, D'Amico M, Di Filippo C, Marfella R, Nappo F, Berrino L, Rossi F, Giugliano D: Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes. 2002, 51: 1076-1082. 10.2337/diabetes.51.4.1076.CrossRefPubMed Ceriello A, Quagliaro L, D'Amico M, Di Filippo C, Marfella R, Nappo F, Berrino L, Rossi F, Giugliano D: Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes. 2002, 51: 1076-1082. 10.2337/diabetes.51.4.1076.CrossRefPubMed
42.
go back to reference Xu J, Wu Y, Song P, Zhang M, Wang S, Zou MH: Proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation. 2007, 116: 944-953. 10.1161/CIRCULATIONAHA.106.684795.CrossRefPubMed Xu J, Wu Y, Song P, Zhang M, Wang S, Zou MH: Proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation. 2007, 116: 944-953. 10.1161/CIRCULATIONAHA.106.684795.CrossRefPubMed
43.
go back to reference Wei Q, Xia Y: Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem. 2006, 281: 21652-21659. 10.1074/jbc.M602105200.CrossRefPubMed Wei Q, Xia Y: Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem. 2006, 281: 21652-21659. 10.1074/jbc.M602105200.CrossRefPubMed
44.
go back to reference Kone BC, Kuncewicz T, Zhang W, Yu ZY: Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol. 2003, 285: F178-F190.CrossRefPubMed Kone BC, Kuncewicz T, Zhang W, Yu ZY: Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol. 2003, 285: F178-F190.CrossRefPubMed
45.
go back to reference Stangl V, Lorenz M, Meiners S, Ludwig A, Bartsch C, Moobed M: Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB. 2004, 18: 272-279. 10.1096/fj.03-0054com.CrossRef Stangl V, Lorenz M, Meiners S, Ludwig A, Bartsch C, Moobed M: Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB. 2004, 18: 272-279. 10.1096/fj.03-0054com.CrossRef
46.
go back to reference Govers R, de Bree P, Rabelink TJ: Involvement of the proteasome in activation of endothelial nitric oxide synthase. Life Sci. 2003, 73: 2225-2236. 10.1016/S0024-3205(03)00644-1.CrossRefPubMed Govers R, de Bree P, Rabelink TJ: Involvement of the proteasome in activation of endothelial nitric oxide synthase. Life Sci. 2003, 73: 2225-2236. 10.1016/S0024-3205(03)00644-1.CrossRefPubMed
47.
go back to reference Cai D, Frantz JD, Tawa NE, Melendez PA, Oh BC. Lidov HG: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004, 119: 2852-2898. 10.1016/j.cell.2004.09.027.CrossRef Cai D, Frantz JD, Tawa NE, Melendez PA, Oh BC. Lidov HG: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004, 119: 2852-2898. 10.1016/j.cell.2004.09.027.CrossRef
48.
go back to reference Marfella R, D'Amico M, Esposito K, Baldi A, Di Filippo C, Siniscalchi M, Sasso FC, Portoghese M, Cirillo F, Cacciapuoti F, Carbonara O, Crescenzi B, Baldi F, Ceriello A, Nicoletti GF, D'Andrea F, Verza M, Coppola L, Rossi F, Giugliano D: The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes. 2006, 55: 622-632. 10.2337/diabetes.55.03.06.db05-0832.CrossRefPubMed Marfella R, D'Amico M, Esposito K, Baldi A, Di Filippo C, Siniscalchi M, Sasso FC, Portoghese M, Cirillo F, Cacciapuoti F, Carbonara O, Crescenzi B, Baldi F, Ceriello A, Nicoletti GF, D'Andrea F, Verza M, Coppola L, Rossi F, Giugliano D: The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes. 2006, 55: 622-632. 10.2337/diabetes.55.03.06.db05-0832.CrossRefPubMed
49.
go back to reference Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002, 106: 2067-2072. 10.1161/01.CIR.0000034509.14906.AE.CrossRefPubMed Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002, 106: 2067-2072. 10.1161/01.CIR.0000034509.14906.AE.CrossRefPubMed
50.
go back to reference Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, Marfella R, Giugliano D: Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol. 2002, 139: 1145-1150. 10.1016/S0735-1097(02)01741-2.CrossRef Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, Marfella R, Giugliano D: Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol. 2002, 139: 1145-1150. 10.1016/S0735-1097(02)01741-2.CrossRef
51.
go back to reference Katagiri K, Yokosawa H, Kinashi T, Kawashima S, Irie S, Tanaka K, Katagiri T: Ubiquitin-proteasome system is involved in induction of LFA-1/ICAM-1-dependent adhesion of HL-60 cells. J Leukoc Biol. 1996, 65: 778-785. Katagiri K, Yokosawa H, Kinashi T, Kawashima S, Irie S, Tanaka K, Katagiri T: Ubiquitin-proteasome system is involved in induction of LFA-1/ICAM-1-dependent adhesion of HL-60 cells. J Leukoc Biol. 1996, 65: 778-785.
52.
go back to reference Lopes-Virella MF, Virella G: Immune mechanism of atherosclerosis in diabetes mellitus. Diabetes. 1992, 41: 86-91. 10.2337/diabetes.41.5.610.CrossRefPubMed Lopes-Virella MF, Virella G: Immune mechanism of atherosclerosis in diabetes mellitus. Diabetes. 1992, 41: 86-91. 10.2337/diabetes.41.5.610.CrossRefPubMed
53.
go back to reference Cominacini L, Fratta Pasini A, Garbin U, Davoli A, De Santis A, Campagnola M, Rigoni A, Zenti MG, Moghetti P, Lo Cascio V: Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia. 1995, 38: 1122-1124. 10.1007/BF00402185.CrossRefPubMed Cominacini L, Fratta Pasini A, Garbin U, Davoli A, De Santis A, Campagnola M, Rigoni A, Zenti MG, Moghetti P, Lo Cascio V: Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia. 1995, 38: 1122-1124. 10.1007/BF00402185.CrossRefPubMed
54.
go back to reference Ceriello A, Falleti E, Bortolotti N, Motz E, Cavarape A, Russo A, Gonano F, Bartoli E: Increased circulating ICAM-1 levels in type-2 diabetic patients: the possible role of metabolic control and oxidative stress. Metabolism. 1996, 45: 498-501. 10.1016/S0026-0495(96)90226-7.CrossRefPubMed Ceriello A, Falleti E, Bortolotti N, Motz E, Cavarape A, Russo A, Gonano F, Bartoli E: Increased circulating ICAM-1 levels in type-2 diabetic patients: the possible role of metabolic control and oxidative stress. Metabolism. 1996, 45: 498-501. 10.1016/S0026-0495(96)90226-7.CrossRefPubMed
55.
go back to reference Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B, Paolisso G, Giugliano D: Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation. 2000, 101: 2247-2251.CrossRefPubMed Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B, Paolisso G, Giugliano D: Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation. 2000, 101: 2247-2251.CrossRefPubMed
56.
go back to reference Krunkosky TM, Martin LD, Fischer BM, Voynow JA, Adler KB: Effects of TNFalpha on expression of ICAM-1 in human airway epithelial cells in vitro: oxidant-mediated pathways and transcription factors. Free Radic Biol Med. 2003, 35: 1158-1167. 10.1016/S0891-5849(03)00498-2.CrossRefPubMed Krunkosky TM, Martin LD, Fischer BM, Voynow JA, Adler KB: Effects of TNFalpha on expression of ICAM-1 in human airway epithelial cells in vitro: oxidant-mediated pathways and transcription factors. Free Radic Biol Med. 2003, 35: 1158-1167. 10.1016/S0891-5849(03)00498-2.CrossRefPubMed
57.
go back to reference Berti R, Williams AJ, Velarde LC, Moffett JR, Elliott PJ, Adams J, Yao C, Dave JR, Tortella FC: Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat. Neurotox Res. 2003, 5: 505-514.CrossRefPubMed Berti R, Williams AJ, Velarde LC, Moffett JR, Elliott PJ, Adams J, Yao C, Dave JR, Tortella FC: Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat. Neurotox Res. 2003, 5: 505-514.CrossRefPubMed
58.
go back to reference Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-234. 10.1056/NEJM199807233390404.CrossRefPubMed Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-234. 10.1056/NEJM199807233390404.CrossRefPubMed
59.
go back to reference Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP: Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med. 1999, 159: 1450-1456. 10.1001/archinte.159.13.1450.CrossRefPubMed Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP: Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med. 1999, 159: 1450-1456. 10.1001/archinte.159.13.1450.CrossRefPubMed
60.
go back to reference Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA. 1999, 281: 1291-1297. 10.1001/jama.281.14.1291.CrossRefPubMed Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA. 1999, 281: 1291-1297. 10.1001/jama.281.14.1291.CrossRefPubMed
61.
go back to reference Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study 4S. Diabetes Care. 1997, 20: 614-620. 10.2337/diacare.20.4.614.CrossRefPubMed Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study 4S. Diabetes Care. 1997, 20: 614-620. 10.2337/diacare.20.4.614.CrossRefPubMed
62.
go back to reference Hansson L, Zanchetti A, Carruthers SG: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment HOT randomised trial. Lancet. 1998, 351: 1755-1762. 10.1016/S0140-6736(98)04311-6.CrossRefPubMed Hansson L, Zanchetti A, Carruthers SG: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment HOT randomised trial. Lancet. 1998, 351: 1755-1762. 10.1016/S0140-6736(98)04311-6.CrossRefPubMed
63.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003, 348: 383-393. 10.1056/NEJMoa021778.CrossRefPubMed Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003, 348: 383-393. 10.1056/NEJMoa021778.CrossRefPubMed
64.
go back to reference Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003, 108: 1772-1778. 10.1161/01.CIR.0000087481.55887.C9.CrossRefPubMed Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003, 108: 1772-1778. 10.1161/01.CIR.0000087481.55887.C9.CrossRefPubMed
65.
go back to reference Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation. 2002, 105: 1135-1143. 10.1161/hc0902.104353.CrossRefPubMed Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation. 2002, 105: 1135-1143. 10.1161/hc0902.104353.CrossRefPubMed
66.
go back to reference Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G: AHA Conference Proceedings Prevention Conference VI: Diabetes and Cardiovascular Disease Writing Group II: Pathogenesis of atherosclerosis in diabetes. Circulation. 2002, 105: 138-148. 10.1161/01.CIR.0000013954.65303.C5.CrossRef Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G: AHA Conference Proceedings Prevention Conference VI: Diabetes and Cardiovascular Disease Writing Group II: Pathogenesis of atherosclerosis in diabetes. Circulation. 2002, 105: 138-148. 10.1161/01.CIR.0000013954.65303.C5.CrossRef
67.
go back to reference Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003, 108: 1664-1672. 10.1161/01.CIR.0000087480.94275.97.CrossRefPubMed Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003, 108: 1664-1672. 10.1161/01.CIR.0000087480.94275.97.CrossRefPubMed
68.
go back to reference Moreno PR, Murcia AM, Palacios IF: Coronary composition and macrophage infiltration in atherectomy specimens from persons with diabetes mellitus. Circulation. 2000, 102: 2180-2184.CrossRefPubMed Moreno PR, Murcia AM, Palacios IF: Coronary composition and macrophage infiltration in atherectomy specimens from persons with diabetes mellitus. Circulation. 2000, 102: 2180-2184.CrossRefPubMed
69.
go back to reference Burke AP, Varghese PJ, Peterson E: Large lipid core and extensive plaque burden are features of coronary atherosclerosis in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol. 2001, 37: 257A.CrossRef Burke AP, Varghese PJ, Peterson E: Large lipid core and extensive plaque burden are features of coronary atherosclerosis in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol. 2001, 37: 257A.CrossRef
70.
go back to reference Marfella R, Di Filippo C, Baldi A, Siniscalchi M, Sasso FC, Crescenzi B, Cirillo F, Nicoletti GF, D'Andrea F, Chiorazzo G, Musacchio E, Rossi F, Verza M, Coppola L, D'Amico M: The vascular smooth muscle cells apoptosis in asymptomatic diabetic carotid plaques: role of glycemic control. J Am Coll Cardiol. 2006, 47: 2118-2120. 10.1016/j.jacc.2006.02.025.CrossRefPubMed Marfella R, Di Filippo C, Baldi A, Siniscalchi M, Sasso FC, Crescenzi B, Cirillo F, Nicoletti GF, D'Andrea F, Chiorazzo G, Musacchio E, Rossi F, Verza M, Coppola L, D'Amico M: The vascular smooth muscle cells apoptosis in asymptomatic diabetic carotid plaques: role of glycemic control. J Am Coll Cardiol. 2006, 47: 2118-2120. 10.1016/j.jacc.2006.02.025.CrossRefPubMed
71.
go back to reference Van Gaal LF, Mertens IL, De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature. 2006, 444: 875-880. 10.1038/nature05487.CrossRefPubMed Van Gaal LF, Mertens IL, De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature. 2006, 444: 875-880. 10.1038/nature05487.CrossRefPubMed
72.
go back to reference Roebuck KA: Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB. Int J Mol Med. 1999, 4: 223-230.PubMed Roebuck KA: Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB. Int J Mol Med. 1999, 4: 223-230.PubMed
73.
go back to reference Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance. diabetes. and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004, 24: 816-823. 10.1161/01.ATV.0000122852.22604.78.CrossRefPubMed Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance. diabetes. and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004, 24: 816-823. 10.1161/01.ATV.0000122852.22604.78.CrossRefPubMed
74.
go back to reference Schmitz ML, Bacher S, Kracht M: I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem Sci. 2001, 26: 186-190. 10.1016/S0968-0004(00)01753-9.CrossRefPubMed Schmitz ML, Bacher S, Kracht M: I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem Sci. 2001, 26: 186-190. 10.1016/S0968-0004(00)01753-9.CrossRefPubMed
75.
go back to reference von der Thusen JH, van Vlijmen BJ, Hoeben RC: Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53". Circulation. 2002, 105: 2064-2070. 10.1161/01.CIR.0000015502.97828.93.CrossRefPubMed von der Thusen JH, van Vlijmen BJ, Hoeben RC: Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53". Circulation. 2002, 105: 2064-2070. 10.1161/01.CIR.0000015502.97828.93.CrossRefPubMed
76.
go back to reference Lu Y, Wahl LM: Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. J Leukoc Biol. 2005, 78: 259-265. 10.1189/jlb.0904498.CrossRefPubMed Lu Y, Wahl LM: Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. J Leukoc Biol. 2005, 78: 259-265. 10.1189/jlb.0904498.CrossRefPubMed
77.
go back to reference Schmitz ML, Bacher S, Kracht M: I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem Sci. 2001, 26: 186-190. 10.1016/S0968-0004(00)01753-9.CrossRefPubMed Schmitz ML, Bacher S, Kracht M: I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem Sci. 2001, 26: 186-190. 10.1016/S0968-0004(00)01753-9.CrossRefPubMed
78.
go back to reference Adams J, Palombella VJ, Elliott PJ: Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000, 18: 109-121. 10.1023/A:1006321828515.CrossRefPubMed Adams J, Palombella VJ, Elliott PJ: Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000, 18: 109-121. 10.1023/A:1006321828515.CrossRefPubMed
79.
go back to reference Barbier O, Torra IP, Duguay Y: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002, 22: 717-726. 10.1161/01.ATV.0000015598.86369.04.CrossRefPubMed Barbier O, Torra IP, Duguay Y: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002, 22: 717-726. 10.1161/01.ATV.0000015598.86369.04.CrossRefPubMed
80.
go back to reference Huang YC, Chuang LY, Hung WC: Mechanisms underlying nonsteroidal anti-inflammatory drug-induced p27Kip1 expression. Mol Pharmacol. 2002, 62: 1515-1521. 10.1124/mol.62.6.1515.CrossRefPubMed Huang YC, Chuang LY, Hung WC: Mechanisms underlying nonsteroidal anti-inflammatory drug-induced p27Kip1 expression. Mol Pharmacol. 2002, 62: 1515-1521. 10.1124/mol.62.6.1515.CrossRefPubMed
Metadata
Title
The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes
Authors
Raffaele Marfella
Michele D' Amico
Clara Di Filippo
Mario Siniscalchi
Ferdinando Carlo sasso
Franca Ferraraccio
Francesco Rossi
Giuseppe Paolisso
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2007
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-6-35

Other articles of this Issue 1/2007

Cardiovascular Diabetology 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.